Glioblastoma Multiforme Treatment (GBM) Market Research Report 2024-2030: Focus on Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global...

Global Glioblastoma Multiforme (GBM) Industry Landscape, 2030 - Featuring Genentech, Merck, VBL Therapeutics, Diffusion Pharma, Bayer, and More Dublin, Dec. 24, 2021 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme (GBM) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. ...

Global Glioblastoma Multiforme Treatment Markets Analysis & Forecasts, 2017-2020 & 2021-2028 Dublin, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By...

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their...